2019 Small Molecule Drug Approvals

2019 was another big year for drug discovery, with 29 FDA novel drug approvals for small molecules (including istradefylline which was first approved in Japan, but not including brilliant blue G, fluorodopa F18, Ga-68-DOTATOC, bremelanotide, afamelanotide, and ferric maltol, which could all be considered small molecules by some definitions) and 3 for antibody-drug-conjugates so far. The ADC approvals include the anti-CD79b agent polatuzumab vedotin (Polivy), the anti-nectin-4 agent enfortumab vedotin (Padcev), and the anti-HER2 agent fam-trastuzumab deruxtecan (Enhertu), all for oncology.

Here is a visual summary of the small molecules with their mechanism of action, indication, and dosing regimen listed (from respective FDA drug labels).

List of 2019 Small Molecule Drug Approvals

List of 2019 Approvals in Oncology (8)

• Alpelisib (Piqray) – PI3Kα-sel. inhibitor
• Erdafitinib (Balversa) – panFGFR inhibitor
• Darolutamide (Nubeqa) – AR antagonist
• Fedratinib (Inrebic – JAK2-selective inhibitor
• Selinexor (Xpovio) – XPO1 inhibitor
• Entrectinib (Rozlytrek) – ROS1/TRK/ALK inhibitor
• Zanubrutinib (Brukinsa) – BTK-selective inhibitor
• Pexidartinib (Turalio) – CSF1R inhibitor

List of 2019 Approvals in Neurology (9)

• Lasmiditan (Reyvow) – 5-HT1_1F -selective agonist
• Ubrogepant (Ulbrelvy) – CGRP receptor antagonist
• Lumateperone (Caplyta) – D_2/5 – HT_2A antagonist
• Pitolisant (Wakix) – H3-selective antagonist/inverse agonist
• Brexanolone (Zulresso) – GABA _AR positive modulator
• Cenobamate (Xcopri) – unclear/GABA_A-modulator
• Siponimod (Mayzent) – S1PR1/5 modulator
• Solriamfetol (Sunosi) – dopamine/norepinephrine reuptake inhibitor
• Lemborexant (Dayvigo) – OX1R/OX2R dual antagonist

List of 2019 Approvals in Infectious Diseases (3) + Other Areas (4)

• Lefamulin (Xenleta) – bacterial ribosome 50S inhibitor
• Triclabendazole (Egaten) – Fasciola anthelmintic
• Tafamidis (Vyndaqel) – specific transthyretin stabilizer
• Voxelotor (Oxbryta) – HbS hemoglobin polymerization inhibitor
• Pretomanid – mycolic acid biosynthesis inhibitor
• Upadacitinib (Rinvoq) – JAK1 -selective inhibitor
• Trifarotene (Aklief) – RARy-selective agonist

Explore drughunter.com for more.